Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the insider directly owned 64,795 shares of the company’s stock, valued at $1,755,296.55. This represents a 4.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 30th, Sarah Gheuens sold 200 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $43.81, for a total value of $8,762.00.
• On Monday, October 27th, Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $43.92, for a total value of $145,023.84.

Agios Pharmaceuticals Trading Down 0.1%

Shares of AGIO stock opened at $27.18 on Monday. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00. The company has a market capitalization of $1.58 billion, a P/E ratio of -3.88 and a beta of 0.89. The stock has a 50 day moving average of $32.20 and a two-hundred day moving average of $35.97.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.Agios Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. During the same period in the previous year, the business posted $16.22 earnings per share. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP grew its holdings in Agios Pharmaceuticals by 31.4% during the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after acquiring an additional 163,796 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth $2,696,000. Frazier Life Sciences Management L.P. grew its stake in shares of Agios Pharmaceuticals by 19.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock worth $42,565,000 after purchasing an additional 209,900 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Agios Pharmaceuticals by 30.7% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company’s stock worth $16,804,000 after purchasing an additional 118,702 shares during the period. Finally, Boothbay Fund Management LLC increased its holdings in Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock valued at $14,868,000 after purchasing an additional 185,798 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AGIO shares. The Goldman Sachs Group decreased their target price on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a research report on Thursday, November 20th. Leerink Partnrs upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 20th. Truist Financial upped their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. HC Wainwright raised their target price on Agios Pharmaceuticals from $48.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, December 26th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.89.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.